Is Ozempic Locking In Diabetes Pricing? Mounjaro’s Reimbursement in Focus

As Novo Nordisk’s Ozempic enters the reimbursed diabetes market at a lower-than-expected price, industry attention is shifting to how rival product Mounjaro, developed by Eli Lilly, will respond. Market participants increasingly view Ozempic’s reimbursement ceiling as a new pricing benchmark—one that could structurally constrain Mounjaro’s reimbursement strategy.

According to industry sources on February 3, Ozempic 2 mg will be reimbursed at $50.67, while the 4 mg formulation will be priced at $96.26 starting this month. This places Ozempic’s treatment cost on par with Lilly’s Trulicity.

Observers interpret the pricing as a deliberate move by Novo Nordisk to capitalize on Ozempic’s clinical profile while directly challenging Trulicity, which has led the diabetes segment for years. The ripple effects, however, extend beyond Trulicity to another key Lilly product: Mounjaro.

Mounjaro is approved for both diabetes and obesity, raising a critical pricing concern. Once a reimbursed price is set for diabetes, it could influence pricing expectations in the non-reimbursed obesity market. The challenge for Lilly is that Ozempic’s reimbursed price came in below market expectations, narrowing room for a premium positioning.

Even if Lilly were to pursue reimbursement negotiations for Mounjaro, industry observers are skeptical that a meaningful premium would be accepted. Some suggest that any reimbursed price would likely struggle to exceed the $140 range.

Lilly is reportedly exploring reimbursement via a dual-pricing structure—often described as a flexible pricing contract—where the listed price differs from the actual transaction price. However, critics note that the effectiveness of such arrangements is limited by the realities of wholesale distribution.

A pharmaceutical industry source said, “Mounjaro is currently sold in the obesity market at around $206.61 on a non-reimbursed basis, with strong demand. If its diabetes reimbursement ceiling were set around $140, Lilly would need to reconsider whether that makes economic sense, given the potential spillover into obesity pricing.”

Another pricing executive added, “In practice, it’s difficult to maintain different wholesale prices for obesity and diabetes indications. The key question is whether Mounjaro chooses to enter the reimbursed market and pursue a volume-driven strategy, or stay out to protect its existing non-reimbursed obesity business.”